Analysis

Novo Nordisk A/s Class B (NVO) Stock Analysis

Novo Nordisk A/s Class B investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to NVO.

websiteNVO/analysis/NVO

Novo Nordisk A/s Class B

Novo Nordisk A/s Class B investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to NVO.

Stock profile

Ticker

NVO

Asset type

Stock

Market cap

$190.45B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Novo Nordisk A/s Class B may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • NOVOB primary listing
  • NVO primary listing
  • NOV
  • NOVO
  • A3EU6F
  • NOVOBC
  • NOVOB80
  • NOVA

Latest Novo Nordisk A/s Class B news

Novo Nordisk A/S: IT Security incident at Novo Nordisk

Bagsværd, Denmark, 11 June 2026 – Novo Nordisk A/S has identified an IT security incident involving unauthorised access to a limited number of internal IT systems. Upon learning...

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults living with obesity and overweight versus placebo in addition to diet...

Novo Nordisk introduces updated Rybelsus® tablet formulation in Canada for adults living with type 2 diabetes

Novo Nordisk today announced the Canadian availability of an updated formulation of Rybelsus® (semaglutide tablets), a prescription medicine used by adults with type 2 diabetes....

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk launches Wegovy® pill in the United Arab Emirates todayWegovy® pill is indicated to reduce excess body weight and maintain weight reduction long-termWegovy® pill, p...

Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2...

Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes As...

Research sections

Valuation

Review valuation context for Novo Nordisk A/s Class B.

Future growth

Review future growth context for Novo Nordisk A/s Class B.

Past performance

Review past performance context for Novo Nordisk A/s Class B.

Financial health

Review financial health context for Novo Nordisk A/s Class B.

Dividend

Review dividend context for Novo Nordisk A/s Class B.

Management

Review management context for Novo Nordisk A/s Class B.

Ownership

Review ownership context for Novo Nordisk A/s Class B.

Other information

Review other information context for Novo Nordisk A/s Class B.

Community

Review community context for Novo Nordisk A/s Class B.